IPSEN, OOO
- Country
- 🇷🇺Russia
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 66
- Registration Number
- NCT05029622
- Locations
- 🇨🇳
Children's Hospital of Fudan University, Changhai, China
🇨🇳Pingxiang Maternity and Child Care, Pingxiang, China
🇨🇳Chengdu Women's & Children's Central Hospital, Chengdu, China
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.
- Conditions
- Interventions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 63
- Registration Number
- NCT05027802
- Locations
- 🇦🇷
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Children's Hospital of Philidelphia, Philadelphia, Pennsylvania, United States
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
- Conditions
- Interventions
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 20
- Registration Number
- NCT05017662
- Locations
- 🇦🇺
Peter Maccallum Cancer Center, Melbourne, Australia
🇦🇹Medical University of Vienna, Vienna, Austria
🇦🇺Ramsay Hollywood Private Hospital, Perth, Australia
A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 45
- Registration Number
- NCT04970407
- Locations
- 🇬🇧
Mac Research Clinical research Unit, Manchester, United Kingdom
Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination
- Conditions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 281
- Registration Number
- NCT04957160
- Locations
- 🇬🇧
Barts Cancer Institute, London, United Kingdom
🇬🇧Royal Surrey County Hospital, Guildford, United Kingdom
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
- Conditions
- Interventions
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 465
- Registration Number
- NCT04936542
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States
🇺🇸Movement Disorders Center of Arizona, Scottsdale, Arizona, United States
Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
- Conditions
- Interventions
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 43
- Registration Number
- NCT04852679
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Sciences, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines
- Conditions
- Interventions
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 727
- Registration Number
- NCT04821089
- Locations
- 🇫🇷
Palais de Flore, Lyon, France
🇫🇷MEDITI - Clinique Del Mar, Antibes, France
🇫🇷Clinique de Chirurgie Esthétique Iéna, Paris, France
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
- Conditions
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 240
- Registration Number
- NCT04752774
- Locations
- 🇺🇸
Rancho Los Amigos National Rehab, Downey, California, United States
🇺🇸Kansas Institute of Research, Overland Park, Kansas, United States
🇺🇸Quest Research Institute, Farmington Hills, Michigan, United States
Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 32
- Registration Number
- NCT04736602
- Locations
- 🇨🇳
Tangshan Maternal & Child Health Hospital, Tangshan, China
🇨🇳Chengdu Women's and Children's Central Hospital, Chengdu, China
🇨🇳Jiangxi Provincial Children's Hospital, Nanchang, China